IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements and discoveries in the field of hematology compiled in an easy-to-digest format. It highlights research breakthroughs, clinical trial results, interesting case studies, and important health advisories – all within the last week. This is a valuable tool for medical professionals with limited time to stay up-to-date on the ever-evolving world of hematology.
IACH News of the week
News of the Week – July 21, 2024 (CLICK TO VIEW)
- CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) for large B-cell lymphomas (LBCL) progressing after CD19-directed CAR T-cell therapy (CAR19): a dose-finding phase 1 study.
- Improved prevention and treatment strategies for differentiation syndrome (DS) contribute to reducing early mortality in patients with acute promyelocytic leukemia (APL): a clinical trial.
- Response-Adapted Ultralow-Dose Radiation Therapy (RT) for Orbital Indolent B-Cell Lymphoma (BCL): A Phase 2 Nonrandomized Controlled Trial.
- An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone (ICD) in patients with newly diagnosed POEMS syndrome.
- The origin of ferritin reference intervals: a systematic review.
News of the Week – July 14, 2024 (CLICK TO VIEW)
- Clinical trial in advanced-stage classical Hodgkin lymphoma (HL): BrECADD versus eBEACOPP.
- Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate (HD-MTX )Treatment for central nervous system (CNS) Lymphoma. A prospective nonrandomized study.
- Mitral regurgitation (MR) is associated with similar loss of von Willebrand factor (VWF) large multimers, but lower frequency of anemia compared with aortic stenosis (AS).
- A systematic review and meta-analysis of nonrelapse mortality (NRM) after chimeric antigen receptor (CAR) T-cell therapy.
- How I Treat: Differentiation Therapy in Acute Myeloid Leukemia (AML).
News of the Week – July 7, 2024 (CLICK TO VIEW)
- Venetoclax and hypomethylating (VEN-HMA) agents in octogenarians and nonagenarians with acute myeloid leukemia (AML).
- Efficacy and safety of bendamustine‐containing bridging therapy (BT) in relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients receiving CD19 chimeric antigen receptor (CAR) T-cells.
- Molecular diagnosis of primary CNS lymphoma (PCNSL) in 2024 using MYD88Leu²⁶⁵Pro and IL-10.
- Response and resistance to menin inhibitor in upstream binding transcription factor (UBTF-TD) acute myeloid leukemia (AML).
- Pembrolizumab and low-dose, single-fraction radiotherapy (RT) for patients with relapsed or refractory multiple myeloma (RRMM).
News of the Month- July 4, 2024 (CLICK TO VIEW)
- Post-transplant cyclophosphamide (PTCy) at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin (ATG) in haploidentical transplantation (Haplo-HCT) with myeloablative conditioning (MAC).
- Younger unrelated donors may be preferable over HLA match in the post-transplant cyclophosphamide (PTCy) era: a study from the ALWP of the EBMT.
- Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation.
- How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.
- Yttrium-90 Anti-CD25-BEAM-Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Peripheral T Cell Lymphoma (PTCL).
- Vedolizumab for the prevention of intestinal acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): a randomized phase 3 trial.
- Evaluation of European LeukemiaNet (ELN) 2022 risk classification in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) for acute myeloid leukemia (AML): Identification of a very poor prognosis genetic group.
- Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia (T-ALL): a registry-based study by the EBMT acute leukemia working party.
- Anti-thymocyte globulin (ATG) or post-transplant cyclophosphamide to prevent graft-versus-host disease (GVHD) in matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (allo-HSCT)?
- Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation (AlloSCT): The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
- Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic stem cell transplantation (AlloSCT).
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM).
- Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma (PCNSL): results of Alliance 51101.
- Graft Failure (GF) Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (AlloSCT) Using Post-Transplant Cyclophosphamide (PTCy).
News of the Week – June 30, 2024 (CLICK TO VIEW)
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma (RRMM).
- Brigatinib in Anaplastic lymphoma kinase (ALK)–positive anaplastic large-cell lymphoma (ALCL) after Failure of Brentuximab Vedotin
- Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1).
- Risk of second tumors and T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy.
- Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia (ET).
- Serum mass spectrometry for treatment monitoring in patients with relapsed/refractory multiple myeloma (RRMM) receiving chimeric antigen receptor (CAR) T-cells.
News of the Week – June 23, 2024 (CLICK TO VIEW)
- Phase 3 study (IMROZ) results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) versus VRD for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)
- Glofitamab (CD20:CD3 bispecific antibody) plus gemcitabine and oxaliplatin (Glofit-GemOx) versus Rituximab(R)-GemOx for Relapsed/Refractory (R/R) Difusse Large B-Cell Lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
- First results of the APOLLO trial: a randomized phase III study to compare arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA [arm A]) versus standard ATRA plus Idarubicin (AIDA regimen [arm B]) for patients with newly diagnosed, high-risk acute promyelocytic leukemia (HR-APL)
- ENERGIZE: a global phase 3 double-blind, randomized, placebo-controlled study of mitapivat demonstrating efficacy and safety in adults with alpha- or beta-non-transfusion-dependent thalassemia (α- or β-NTDT)
- Asciminib (ASC) provides superior efficacy and excellent safety and tolerability versus tyrosine kinase inhibitors (TKI) in newly diagnosed chronic myeloid leukemia (ND-CML) in the pivotal ASC4FIRST study
- The landscape of TP53 mutations and their prognostic impact in Chronic Lymphocytic Leukemia (CLL)
- Acalabrutinib (acala) plus bendamustine and rituximab (BR) in untreated mantle cell lymphoma (MCL): results from the phase 3, double-blind, placebo-controlled ECHO trial
- Guidelines session: EHA-ESMO Clinical Practice Guideline on primary central nervous system lymphoma (PCNSL)
News of the Month – June 7, 2024 (CLICK TO VIEW)
- Abstract number: e1901. Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy
- Abstract number: 7073. Survival outcomes after autologous stem cell transplantation in T follicular helper type lymphoma
- Abstract number: e19043. Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR)
- Abstract number: e1903. Relapsed Hodgkin lymphoma autologous stem cell transplant long term follow up
- Abstract number: 7032. Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
- Donor lymphocyte infusion (DLI) after allogeneic hematopoietic cell transplantation (allo-HCT) for hematological malignancies.
- From 50th Annual Meeting of the EBMT
- Fecal microbiota transplantation for high-risk treatment-naïve acute graft-versus-host disease (GVHD)
- Peripheral blood (PB) stem cell versus bone marrow (BM) graft in reduced intensity conditioning (RIC) haploidentical hematopoietic stem cell transplantation (Haplo-SCT) for acute myeloid leukemia (AML) in complete remission (CR)
- Improved outcome of allogeneic transplantation (AlloSCT) in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide (PTCy) and reduced duration of immune suppression
- Efficacy of autologous (AutoSCT) and allogeneic hematopoietic cell transplantation (AlloSCT) in adults with acute promyelocytic leukemia (APL)
News of the Week – June 2, 2024 (CLICK TO VIEW)
- Oral azacitidine in patients with relapsed or refractory follicular helper T-cell lymphoma
- Risk stratification in Waldenström macroglobulinemia
- VEXAS syndrome and thrombosis
- Tattoos as a risk factor for malignant lymphoma
- Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor (CAR)-T cell therapy in clinical practice for relapsed and refractory multiple myeloma
News of the Week – May 26, 2024 (CLICK TO VIEW)
- Monoclonal Gammopathy of Undetermined Significance
- Multiple myeloma and minimal residual disease
- Multiple myeloma and chimeric antigen receptor-T cell therapy
- Relapsed/refractory large B‐cell lymphoma
News of the Week – May 19, 2024 (CLICK TO VIEW)
- Mature T- and NK-cell neoplasms
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Multiple myeloma
News of the Week – May 12, 2024 (CLICK TO VIEW)
- Measurable residual disease in multiple myeloma
- “Minimal” residual disease in multiple myeloma
- Untreated mantle cell lymphoma
- Immune thrombotic thrombocytopenia purpura treatment
- Relapsed or refractory primary mediastinal large B-cell lymphoma
- Relapsed or refractory marginal zone lymphoma
News of the Week – May 5, 2024 (CLICK TO VIEW)
- Chimeric antigen receptor (CAR) T-cells, bispecific antibodies (BsAbs), and relapsed and refractory large B-cell lymphoma (R/R LBCL)
- Chimeric antigen receptor (CAR) T-cells and Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
- Myelodysplastic syndromes (MDS)
- Acute myeloid leukemia (AML)
- Monoclonal B-cell lymphocytosis (MBL)
News of the Week – April 28, 2024 (CLICK TO VIEW)
- Hemoglobinopathies & gene edition
- Chimeric antigen receptor T cell (CAR T) therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- Primary sinonasal diffuse large B-cell lymphoma (PSDLBCL)
- Polycythemia vera (PV)
- Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome
- Post-transplant lymphoproliferative disorder (PTLPD)
News of the Week – April 21, 2024 (CLICK TO VIEW)
- Chronic graft-vs-host disease (cGVHD)
- Immune effector cell therapy-associated cytokine release syndrome
- Multiple myeloma (MM) and chimeric antigen receptor T (CAR T) cell therapy
- Non-Hodgkin lymphoma (NHL) and bispecific antibodies (BsAb)
- Diffuse large B-cell lymphoma (DLBCL)
News of the Week – April 14, 2024 (CLICK TO VIEW)
- Acute myeloid leukemia (AML)
- Infections in secondary hypogammaglobulinemia in hematological malignancies.
- Relapsed/refractory multiple myeloma (RRMM)
- Cardiotoxicity and non-Hodgkin lymphoma (NHL)
- Triple negative-primary myelofibrosis (TN-PMF)
- Mature T-cell lymphomas (TCL) and chimeric antigen receptor T (CAR T) therapies
News of the Week – April 7, 2024 (CLICK TO VIEW)
- AL amyloidosis
- Monoclonal gammopathy of undetermined significance (MGUS)
- Extranodal natural killer/T cell lymphoma (ENKTL)
- Chimeric antigen receptor T (CAR T) therapies
- Acute myeloid leukemia (AML)
News of the Week – March 31, 2024 (CLICK TO VIEW)
- Primary immune thrombocytopenia (ITP) therapies
- Primary testicular lymphoma (pTL)
- Hemophilia B
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Multiple myeloma (MM)
- Hematopoietic cell transplantation (HCT) and cellular therapies.
News of the Week – March 24, 2024 (CLICK TO VIEW)
- Chimeric antigen receptor T cell (CAR-T) therapies
- Acute myeloid leukemia (AML)
- B-cell malignancies
- Central nervous system (CNS) B-cell lymphoma
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- Myelofibrosis
News of the Week – March 17, 2024 (CLICK TO VIEW)
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Autoimmune hemolytic anemia (AIHA)
News of the Week – March 10, 2024 (CLICK TO VIEW)
- Multiple myeloma (MM) – DREAMM-8 phase III trial (NCT04484623)
- T-prolymphocytic leukemia (T-PLL) – phase II study (NCT03873493)
- High-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) – safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine
- Aplastic anemia (AA) – SOAR (NCT02998645)
- Chimeric antigen receptor (CAR)-T-cell therapy – Rare secondary T-cell lymphomas after CD19- and BCMA-directed CAR-T-cell therapy